Carl Firth

Dr Carl Firth is Chief Executive Officer of ASLAN Pharmaceuticals, a US-listed clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Prior to founding ASLAN, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions. Before joining the banking industry, Carl worked for AstraZeneca across various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Carl holds board positions at various biotechs, including JAGUAHR Therapeutics and DotBio, and is an independent director of A*ccelerate, the commercialisation arm of Singapore’s Agency for Science, Technology and Research (A*STAR). Previously, Carl served as an independent director of Hong Kong listed Uni-Bio Sciences, a commercial stage Chinese pharmaceutical company, and was a member of Singapore’s Health and Biomedical Sciences International Advisory Council. Carl is an Adjunct Professor at Duke-NUS Medical School. He has a PhD in Molecular Biology from Cambridge University (Trinity College), an Executive MBA from London Business School; and a BA in Molecular Biology from Cambridge University.